04-Apr-2023

AI Opportunities in Personalised Medicine 2023: Dawn of the AI Era Set to Unlock New Understanding of Disease Pathologies - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "AI Opportunities in Personalised Medicine" report has been added to ResearchAndMarkets.com's offering.

Know how advanced AI analytics can transform your personalised medicines strategy

Multimodal Artificial Intelligence (AI)-enabled analytics are integrating insights from genomics, epigenomics, metabolomics, proteomics and transcriptomics. Allied to imaging data, laboratory tests, electronic health records and real-world data, AI is unlocking a deep understanding of the pathology of diseases and their treatment.

So how and where can pharma best leverage value from its AI investment to inform and drive drug discovery, development and personalised medicines programs? For expert insights into the latest developments turn to this report.

Key Topics Covered:

Subject synopsis
Research methodology and objectives
- Experts interviewed
- Key research objectives
Key insights summary
Issues and insights
- Current application of AI by the pharma industry
  - Issue summary
  - Questions
  - Key insights
  - Supporting quotes
  - Intelligence exhibits
- Multiomics data to drive AI algorithms and the personalisation of medicine
  - Issue summary
  - Questions
  - Key insights
  - Supporting quotes
  - Intelligence exhibits
- AI transforming the pharma business model
  - Issue summary
  - Questions
  - Key insights
  - Supporting quotes
  - Intelligence exhibits
- Future applications of AI and multiomics in the evolution of personalised medicine
  - Issue summary
  - Questions
  - Key insights
  - Supporting quotes
  - Intelligence exhibits
Further Reading
Definitions
Abbreviations

Companies Mentioned

AbbVie
Absci
Adapsyn
Amgen
Andson Biotech
Anima Biotech
Artios
AstraZeneca
Astrogen
Atomwise
Aurora
Baidu
Bayer
BenevolentAI
Berg
BioAI Health
Biodesy
Biogen
BioSymetrics
Biovista
Black Diamond Therapeutics
Boehringer Ingelheim
Bristol Myers Squibb
C4X Discovery
Centogene
Cyclica
CytoReason
Datavant
Deep Forest Sciences
DeepMind
Dyno Therapeutics
e-therapeutics
Elix
Envisagenics
EQRx
Evaxion Biotech
Evotec
Evozyne
Exscientia
Facebook
Flatiron Health
Fosun Pharma
Foundation Medicine
Genentech
Genesis Therapeutics
Genialis
Gesund.ai
GlaxoSmithKline
GNS Healthcare
Google
Google Quantum AI
Harbour BioMed
IBM Research
Iktos
Illumina
IndyGeneUS AI
Innoplexus
Insilico Medicine
Insitro
Johnson & Johnson
Jubilant Therapeutics
JW Pharmaceutical
Kymera Therapeutics
Lantheus
Lilly
Magna Labs
MedImmune
Merck & Co.
Merck Group
Microsoft
Multiomic Health
Nanna Therapeutics
NEC Corporation
Nimbus Therapeutics
Novartis
Novo Nordisk
Nuritas
NVIDIA
Oncoceutics
OneThree Biotech
Ono Pharmaceutical
OpenAI
Orbis
Owkin
PathAI
Pepper Bio
Perceiv AI
Pfizer
Pharos iBio
PhoreMost
Poolbeg Pharma
ProteinQure
Qiagen
QSimulate
Qure.ai
Recursion
Relay Therapeutics
Researchably
Resonant Therapeutics
Reverie Labs
Roche
Saama Technologies
Sanofi
Santen
Schrodinger
SciMar ONE
Shionogi
Sirenas
SK Life Science
Standigm
STEM Healthcare
Sumitomo Dainippon
Sun Pharma
Sun Pharma Advanced Research Company
Syapse
Systems Oncology
Takeda
Teijin Pharma
Tencent
Teva
ThinkCyte
twoXAR Turbine
Verantos
Verge Genomics
Wave Life Sciences
WuXi
XtalPi

For more information about this report visit https://www.researchandmarkets.com/r/ua6ab3

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

Company:
- Businesswire

Last Updated: 04-Apr-2023